Recombinant PDCD1 (Pembrolizumab Biosimilar) anticorps

N° du produit ABIN7487773

L’anticorps Mammalian Cells Monoclonal anti-PDCD1 (Pembrolizumab Biosimilar) a été validé pour ELISA. Il convient pour détecter PDCD1 (Pembrolizumab Biosimilar) dans des échantillons de Humain.

Aperçu rapide pour Recombinant PDCD1 (Pembrolizumab Biosimilar) anticorps (ABIN7487773)

Antigène: PDCD1 (Pembrolizumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Mammalian Cells

Clonalité: Monoclonal

Conjugué: Cet anticorp PDCD1 (Pembrolizumab Biosimilar) est non-conjugé

Application: ELISA

Classe de qualité: Research Grade

Détail du produit anti-PDCD1 (Pembrolizumab Biosimilar) anticorps

Expression System: Mammalian cells

Fonction: Pembrolizumab Biosimilar - Anti-PD1 mAb

Attributs du produit: Antibody Type: IgG4

Purification: Recombinant antibody expressed in mammalien cells and purified.

Isotype: IgG4

Information d'application

Restrictions: For Research Use only

Stockage

Buffer: PBS pH 7.5

Stock: 4 °C,-20 °C

Stockage commentaire: 4°C for short term, -20°C for long term

Détails sur PDCD1 (Pembrolizumab Biosimilar)

Antigène: PDCD1 (Pembrolizumab Biosimilar)

Classe de substances: Biosimilar

Sujet: Pembrolizumab
Pembrolizumab is a humanized (from mouse) monoclonal antibody that binds to, and blocks PD-1 located on lymphocytes. It is an anticancer medication used in the treatment of melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, urothelial cancer (cancer of the bladder and urinary tract) and renal cell carcinoma (kidney cancer).